Antibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort.
Amoxicillin
/ therapeutic use
Anti-Bacterial Agents
/ therapeutic use
Antibiotic Prophylaxis
Cephalosporins
Cohort Studies
Escherichia coli
Female
Fetal Membranes, Premature Rupture
/ prevention & control
Gestational Age
Humans
Infant
Infant, Newborn
Infant, Premature
Macrolides
Neonatal Sepsis
Pregnancy
Pregnancy Outcome
Premature Birth
/ prevention & control
Prospective Studies
amoxicillin
antenatal management
cephalosporins
latency
macrolides
neurodevelopment
obstetric intervention
perinatal outcome
prematurity
prophylactic antibiotics
Journal
BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
05
10
2021
received:
24
05
2021
accepted:
05
11
2021
pubmed:
27
12
2021
medline:
14
7
2022
entrez:
26
12
2021
Statut:
ppublish
Résumé
To compare different antibiotic prophylaxis administered after preterm premature rupture of membranes to determine whether any were associated with differences in obstetric and/or neonatal outcomes and/or neurodevelopmental outcomes at 2 years of corrected age. Prospective, nationwide, population-based EPIPAGE-2 cohort study of preterm infants. France, 2011. We included 492 women with a singleton pregnancy and a diagnosis of preterm premature rupture of membranes at 24-31 weeks. Exclusion criteria were contraindication to expectant management or indication for antibiotic therapy other than preterm premature rupture of membranes. Antibiotic prophylaxis was categorised as amoxicillin (n = 345), macrolide (n = 30), third-generation cephalosporin (n = 45) or any combinations covering Streptococcus agalactiae and >90% of Escherichia coli (n = 72), initiated within 24 hours after preterm premature rupture of membranes. Population-averaged robust Poisson models. Survival at discharge without severe neonatal morbidity, 2-year neurodevelopment. With amoxicillin, macrolide, third-generation cephalosporin and combinations, 78.5%, 83.9%, 93.6% and 86.0% of neonates were discharged alive without severe morbidity. The administration of third-generation cephalosporin or any E. coli-targeting combinations was associated with improved survival without severe morbidity (adjusted risk ratio 1.25 [95% confidence interval 1.08-1.45] and 1.10 [95 % confidence interval 1.01-1.20], respectively) compared with amoxicillin. We evidenced no increase in neonatal sepsis related to third-generation cephalosporin-resistant pathogen. In preterm premature rupture of membranes at 24-31 weeks, antibiotic prophylaxis based on third-generation cephalosporin may be associated with improved survival without severe neonatal morbidity when compared with amoxicillin, with no evidence of increase in neonatal sepsis related to third-generation cephalosporin-resistant pathogen. Antibiotic prophylaxis after PPROM at 24-31 weeks: 3rd-generation cephalosporins associated with improved neonatal outcomes.
Identifiants
pubmed: 34954867
doi: 10.1111/1471-0528.17081
pmc: PMC9546066
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
Macrolides
0
Amoxicillin
804826J2HU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1560-1573Subventions
Organisme : Fondation des Treilles
Organisme : National Research Agency
ID : ANR-11-EQPX-0038
Organisme : French Institute of Public Health Research/Institute of Public Health
ID : IRESP TGIR 2009-01
Organisme : French Health Ministry
Organisme : National Institute of Health and Medical Research (INSERM)
Organisme : National Institute of Cancer
Organisme : National Solidarity Fund for Autonomy (CNSA)
Organisme : PREMUP Foundation
Organisme : Fondation pour la Recherche Medicale
ID : SPF 20160936356
Organisme : Fondation de France
ID : Grant 00050329
Organisme : Fondation de France
ID : Grand Prix R18202KK
Organisme : Universite de Geneve
Investigateurs
Pierre-Yves Ancel
(PY)
Catherine Arnaud
(C)
Julie Blanc
(J)
Thierry Debillon
(T)
Pierre Delorme
(P)
Claude D'Ercole
(C)
Thomas Desplanches
(T)
Caroline Diguisto
(C)
Géraldine Gascoin
(G)
Catherine Gire
(C)
François Goffinet
(F)
Bruno Langer
(B)
Emeline Maisonneuve
(E)
Stéphane Marret
(S)
Isabelle Monier
(I)
Andrei Morgan
(A)
Jean-Christophe Rozé
(JC)
Thomas Schmitz
(T)
Loïc Sentilhes
(L)
Damien Subtil
(D)
Barthélémy Tosello
(B)
Christophe Vayssière
(C)
Norbert Winer
(N)
Jennifer Zeitlin
(J)
D Astruc
(D)
P Kuhn
(P)
J Matis
(J)
C Ramousset
(C)
X Hernandorena
(X)
P Chabanier
(P)
L Joly-Pedespan
(L)
M J Costedoat
(MJ)
A Leguen
(A)
B Lecomte
(B)
D Lemery
(D)
F Vendittelli
(F)
G Beucher
(G)
M Dreyfus
(M)
B Guillois
(B)
Y Toure
(Y)
A Burguet
(A)
S Couvreur
(S)
J B Gouyon
(JB)
P Sagot
(P)
N Colas
(N)
J Sizun
(J)
A Beuchée
(A)
P Pladys
(P)
F Rouget
(F)
R P Dupuy
(RP)
D Soupre
(D)
F Charlot
(F)
S Roudaut
(S)
A Favreau
(A)
E Saliba
(E)
L Reboul
(L)
N Bednarek
(N)
P Morville
(P)
V Verrière
(V)
G Thiriez
(G)
C Balamou
(C)
L Marpeau
(L)
C Barbier
(C)
X Durrmeyer
(X)
M Granier
(M)
M Ayoubi
(M)
O Baud
(O)
B Carbonne
(B)
P H Jarreau
(PH)
D Mitanchez
(D)
C Duffaut
(C)
L Cornu
(L)
R Moras
(R)
P Boulot
(P)
G Cambonie
(G)
H Daudé
(H)
A Badessi
(A)
N Tsaoussis
(N)
A Bédu
(A)
F Mons
(F)
C Bahans
(C)
M H Binet
(MH)
J Fresson
(J)
J M Hascoët
(JM)
A Milton
(A)
O Morel
(O)
R Vieux
(R)
L Hilpert
(L)
C Alberge
(C)
M Baron
(M)
M L Charkaluk
(ML)
V Pierrat
(V)
P Truffert
(P)
S Akowanou
(S)
U Simeoni
(U)
A Bongain
(A)
M Deschamps
(M)
B Branger
(B)
V Rouger
(V)
C Dupont
(C)
J Gondry
(J)
G Krim
(G)
B Baby
(B)
M Debeir
(M)
O Claris
(O)
J C Picaud
(JC)
S Rubio-Gurung
(S)
C Cans
(C)
A Ego
(A)
H Patural
(H)
A Rannaud
(A)
E Janky
(E)
A Poulichet
(A)
J M Rosenthal
(JM)
E Coliné
(E)
A Favre
(A)
N Joly
(N)
S Châlons
(S)
J Pignol
(J)
P L Laurence
(PL)
P Y Robillard
(PY)
S Samperiz
(S)
D Ramful
(D)
B Blondel
(B)
M Bonet
(M)
A Brinis
(A)
A Coquelin
(A)
M Durox
(M)
M Kaminski
(M)
K Khemache
(K)
B Khoshnood
(B)
C Lebeaux
(C)
L Marchand-Martin
(L)
J Rousseau
(J)
M J Saurel-Cubizolles
(MJ)
D Tran
(D)
Informations de copyright
© 2022 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.
Références
Lancet. 2001 Mar 31;357(9261):979-88
pubmed: 11293640
Am J Obstet Gynecol. 2008 Dec;199(6):620.e1-8
pubmed: 18973872
Am J Obstet Gynecol. 2012 Feb;206(2):119-23
pubmed: 22177191
Obstet Gynecol. 2020 Mar;135(3):e80-e97
pubmed: 32080050
Eur J Pediatr. 2012 Apr;171(4):681-7
pubmed: 22134805
Trends Mol Med. 2015 Feb;21(2):109-17
pubmed: 25578246
Ultrasound Obstet Gynecol. 2020 Jan;55(1):20-31
pubmed: 31633844
Pediatrics. 2010 May;125(5):e1031-8
pubmed: 20385650
Obstet Gynecol. 2003 Jan;101(1):178-93
pubmed: 12517665
Lancet. 2008 Oct 11;372(9646):1319-27
pubmed: 18804276
Am J Clin Nutr. 2015 Oct;102(4):721-8
pubmed: 26245806
J Pediatr. 2015 Mar;166(3):515-7
pubmed: 25596102
BMC Med Res Methodol. 2018 Jun 22;18(1):63
pubmed: 29929477
Semin Perinatol. 2017 Nov;41(7):409-419
pubmed: 28807394
Eur J Obstet Gynecol Reprod Biol. 2019 May;236:1-6
pubmed: 30870741
Lancet. 2008 Oct 11;372(9646):1310-8
pubmed: 18804274
J Obstet Gynaecol Can. 2017 Sep;39(9):e207-e212
pubmed: 28859768
Int J Infect Dis. 2020 Jul;96:254-259
pubmed: 32407901
Clin Microbiol Rev. 2016 Dec 14;30(1):349-379
pubmed: 27974410
Gynecol Obstet Fertil Senol. 2018 Dec;46(12):1043-1053
pubmed: 30392988
Obstet Gynecol. 2017 Aug;130(2):e95-e101
pubmed: 28742677
BJOG. 2019 Aug;126(9):e152-e166
pubmed: 31207667
Am J Epidemiol. 2003 May 15;157(10):940-3
pubmed: 12746247
BMJ. 2017 Aug 16;358:j3448
pubmed: 28814566
Am J Obstet Gynecol. 1999 Oct;181(4):816-21
pubmed: 10521735
Am J Obstet Gynecol. 2008 May;198(5):e54-6
pubmed: 18455521
BJOG. 2022 Aug;129(9):1560-1573
pubmed: 34954867
PLoS One. 2018 Nov 7;13(11):e0206290
pubmed: 30403730
Dev Med Child Neurol. 2000 Dec;42(12):816-24
pubmed: 11132255
Early Hum Dev. 2019 Aug;135:6-10
pubmed: 31177037
Clin Microbiol Rev. 2013 Oct;26(4):744-58
pubmed: 24092853
JAMA Pediatr. 2015 Mar;169(3):230-8
pubmed: 25621457
BJOG. 2016 May;123(6):983-93
pubmed: 26412384
J Matern Fetal Neonatal Med. 2016 Mar;29(5):707-20
pubmed: 26373262
JAMA. 1997 Sep 24;278(12):989-95
pubmed: 9307346
Int J Epidemiol. 2021 Nov 10;50(5):1428-1429m
pubmed: 34165536
Cochrane Database Syst Rev. 2013 Dec 02;(12):CD001058
pubmed: 24297389
J Pediatr. 2017 Mar;182:47-52.e2
pubmed: 28081890
Am J Obstet Gynecol. 2004 Oct;191(4):1497-502
pubmed: 15507990
Clin Microbiol Infect. 2018 Jan;24(1):3-5
pubmed: 28970162
J Pediatr. 2015 Mar;166(3):538-44
pubmed: 25444008
J Gynecol Obstet Biol Reprod (Paris). 2016 Feb;45(2):155-64
pubmed: 26422365
J Pediatr. 2020 Jul;222:71-78.e6
pubmed: 32586536
Int J Antimicrob Agents. 2018 Dec;52(6):762-770
pubmed: 30176355
Lancet. 2008 Jan 5;371(9606):75-84
pubmed: 18177778
Arch Dis Child Fetal Neonatal Ed. 2020 Jul;105(4):425-431
pubmed: 31732683